Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-05 13:46:06 - browse：45911

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Histogen: Failed biotech offers rare public look inside

entertainment

WSS

Analysis of telehealth claims data suggest service duplication

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

A Q&A with the global head of Boehringer Ingelheim's innovation unit

When women are denied an abortion, their children fare worse than peers

'The Exorcist' director William Friedkin dead at 87

Moderna hits safety problems in bold bid to reinvent medicine

focus

Wikipedia

focus

23andMe had bad news about my health. I wish a person had delivered it

VC firm General Catalyst wants to buy a health system

What does generative AI mean for health care? We asked experts

Analysis of telehealth claims data suggest service duplication

State Dept. review finds Biden bears some blame for Afghanistan failures

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Walensky prepares to leave CDC — and Congress — behind

Mississippi candidates for statewide offices square off in party primaries

Alkermes shareholders re

Senate panel eyes new effort on drug shortages

leisure time

Analysis of telehealth claims data suggest service duplication

Chemotherapy drug shortage eases slightly but still widespread

A Q&A with the global head of Boehringer Ingelheim's innovation unit

The future of health care in the House

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Why Charlie Gard's case is so disturbing to Americans

entertainment

focus

entertainment

leisure time